Envista Holdings Co. (NYSE:NVST – Free Report) – Equities researchers at Leerink Partnrs lifted their FY2024 EPS estimates for Envista in a research note issued to investors on Thursday, October 31st. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings per share of $0.70 for the year, up from their previous estimate of $0.68. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Envista’s current full-year earnings is $0.69 per share. Leerink Partnrs also issued estimates for Envista’s Q1 2025 earnings at $0.22 EPS, Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.32 EPS and FY2026 earnings at $1.28 EPS.
Envista (NYSE:NVST – Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.59%. The company had revenue of $601.00 million for the quarter, compared to analysts’ expectations of $590.34 million. During the same period last year, the firm earned $0.43 earnings per share. The business’s revenue for the quarter was down 4.8% on a year-over-year basis.
Check Out Our Latest Stock Analysis on NVST
Envista Stock Down 0.1 %
Shares of NVST opened at $20.94 on Friday. Envista has a 12 month low of $15.15 and a 12 month high of $25.64. The firm’s 50 day moving average is $18.64 and its 200-day moving average is $18.08. The stock has a market capitalization of $3.60 billion, a PE ratio of -2.69 and a beta of 1.32. The company has a current ratio of 2.22, a quick ratio of 1.90 and a debt-to-equity ratio of 0.47.
Insider Transactions at Envista
In other Envista news, CFO Eric D. Hammes purchased 24,532 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were bought at an average price of $16.33 per share, for a total transaction of $400,607.56. Following the completion of the acquisition, the chief financial officer now owns 24,532 shares in the company, valued at approximately $400,607.56. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by company insiders.
Hedge Funds Weigh In On Envista
Hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Envista during the third quarter worth $31,000. GAMMA Investing LLC raised its stake in Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after buying an additional 726 shares during the last quarter. Blue Trust Inc. raised its stake in Envista by 69.7% during the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after buying an additional 804 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Envista by 50.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after buying an additional 728 shares during the last quarter. Finally, Versant Capital Management Inc raised its stake in Envista by 1,420.3% during the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock worth $52,000 after buying an additional 2,940 shares during the last quarter.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Articles
- Five stocks we like better than Envista
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- When to Sell a Stock for Profit or Loss
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Investing In Automotive Stocks
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.